Abstract

The amphilimus-eluting stent (AES) is a thin-strut polymer-free stent that releases sirolimus formulated with a carrier from abluminal grooves. The RESERVOIR trial compared AES vs everolimus-eluting stents (EES) in patients with diabetes mellitus (DM) and showed non-inferior neointimal hyperplasia suppression at 9 months follow-up. The aim of this study was to assess comparative clinical outcomes at 5 years. The endpoints analyzed for this extended follow-up were target-vessel failure (TVF), target-vessel revascularization (TVR) and target-lesion revascularization (TLR). At 5-years, AES vs EES had similar risk of TVF (HR 0.54, 95% CI 0.20–1.47, p = 0.23), TVR (HR 0.36, 95% CI 0.12–1.14, p = 0.08) and TLR (HR 0.43, 95%CI 0.11–1.67, p = 0.22). Landmark analyses between 1 and 5 years also showed no significant differences between groups.